Repros rises again on second Phase III Androxal data set
This article was originally published in Scrip
Executive Summary
Already riding high on Phase III data for Androxal, Repros Therapeutics was buoyed on 17 September by positive results from a second pivotal study in the treatment of secondary hypogonadism and a safety study for the company's oral testosterone therapy.